Sign In
Buy RGNX
$12.75
-1.20 (-8.60%)
At Close: Jul 13, 2026
New long-term data from diabetic retinopathy and wet AMD programs to be presented at American Society of Retina Specialists (ASRS) 2026 ROCKVILLE, Md., June 29, 2026 /PRNewswire/ -- REGENXBIO Inc. (N
Regenxbio: 'Strong Buy' On FDA Course Reversal For NAVSUNLI And Potential AA DMD Filing
08:45am, Sunday, 28'th Jun 2026
REGENXBIO upgraded to 'Strong Buy' on FDA's course reversal for rare disease therapies, notably impacting NAVSUNLI [RGX-121] for MPS II. Company expects to resubmit NAVSUNLI BLA in Q3 2026, leveraging
Confirmatory study completed ahead of schedule due to strong patient demand and robust investigator interest On track to initiate BLA in Q3 2026 under the accelerated approval pathway supporting poten
Regenxbio Shares Rise on Plans to Resubmit Navsunli BLA for MPS II
11:51am, Tuesday, 23'rd Jun 2026
RGNX shares jump after FDA alignment on next steps for Navsunli, paving the way for a planned MPS II BLA resubmission in Q3 2026.
Regenxbio Gains Fresh Chance As FDA Reconsiders Gene Therapy
09:23am, Monday, 22'nd Jun 2026
Regenxbio Inc. (NASDAQ:RGNX) on Monday said it aligned with the Food and Drug Administration (FDA) regarding the next steps needed for a potential accelerated approval of Navsunli (RGX-121, clemidsoge
FDA confirmed no additional studies required, existing longer-term data from the CAMPSIITE ® study will be reviewed on an expedited basis for approval via the accelerated approval pathway The Company
FDA to reverse rejection of Regenxbio's rare-disease drug, WSJ reports
07:01am, Monday, 22'nd Jun 2026
The U.S. Food and Drug Administration will reverse its earlier rejection of a rare-disease therapy from Regenxbio , the Wall Street Journal reported on Monday
FDA Will Reverse Rejection of Third Rare-Disease Drug, Regenxbio Says
06:30am, Monday, 22'nd Jun 2026
The company plans to refile its application for its gene therapy for a fatal brain disease after the FDA dropped demands to give a placebo to some study subjects.
REGENXBIO Inc. (RGNX) Presents at RBC Capital Markets Global Healthcare Conference 2026 Transcript
04:20pm, Friday, 22'nd May 2026
REGENXBIO Inc. (RGNX) Presents at RBC Capital Markets Global Healthcare Conference 2026 Transcript
REGENXBIO to Participate in Upcoming Investor Conferences
04:05pm, Monday, 18'th May 2026
ROCKVILLE, Md., May 18, 2026 /PRNewswire/ -- REGENXBIO Inc. (Nasdaq: RGNX) today announced it will participate in the following investor conferences: 2026 RBC Capital Markets Global Healthcare Confer
REGENXBIO Inc. (RGNX) Q1 2026 Earnings Call Transcript
08:30pm, Thursday, 14'th May 2026
REGENXBIO Inc. (RGNX) Q1 2026 Earnings Call Transcript
REGENXBIO Advances Duchenne Gene Therapy Toward Accelerated Approval
12:03pm, Thursday, 14'th May 2026
REGENXBIO Inc. (NASDAQ:RGNX) on Thursday released topline and interim functional data from the pivotal Phase 1/2/3 AFFINITY DUCHENNE trial evaluating RGX-202, its investigational gene therapy for Duch
Regenxbio (RGNX) Reports Q1 Loss, Lags Revenue Estimates
09:30am, Thursday, 14'th May 2026
Regenxbio (RGNX) came out with a quarterly loss of $1.72 per share versus the Zacks Consensus Estimate of a loss of $1.36. This compares to earnings of $0.12 per share a year ago.
REGENXBIO Reports First Quarter 2026 Financial Results and Operational Highlights
07:10am, Thursday, 14'th May 2026
Company announced positive topline results from pivotal Phase III AFFINITY DUCHENNE ® study of RGX-202 Primary endpoint achieved with high statistical significance Statistically significant correlati
Regenxbio's muscle disorder therapy meets main goal in late-stage study
07:04am, Thursday, 14'th May 2026
Regenxbio said on Thursday that its experimental therapy to treat a muscle-wasting disorder met the main goal in a late-stage study.
